Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| 1 |
Broadcom
AVGO
|
+$2.06B |
| 2 |
Nasdaq
NDAQ
|
+$1.76B |
| 3 |
Wells Fargo
WFC
|
+$1.1B |
| 4 |
Gilead Sciences
GILD
|
+$978M |
| 5 |
Edwards Lifesciences
EW
|
+$964M |
Top Sells
| 1 |
EOG Resources
EOG
|
+$1.82B |
| 2 |
Apple
AAPL
|
+$1.75B |
| 3 |
HCA Healthcare
HCA
|
+$1.51B |
| 4 |
SPDR S&P 500 ETF Trust
SPY
|
+$1.48B |
| 5 |
PNC Financial Services
PNC
|
+$1.29B |
Sector Composition
| 1 | Technology | 23.24% |
| 2 | Healthcare | 19.6% |
| 3 | Financials | 13.95% |
| 4 | Consumer Discretionary | 9.41% |
| 5 | Industrials | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1601
Esperion Therapeutics
ESPR
$506M
| $995K | ﹤0.01% |
602,936
+241,512
| +67% | +$398K |
|
1602
Highwoods Properties
HIW
$3.44B
| $990K | ﹤0.01% |
29,531
-74,828
| -72% | -$2.51M |
|
1603
Heron Therapeutics
HRTX
$199M
| $987K | ﹤0.01% |
496,227
-24,967
| -5% | -$49.7K |
|
1604
Jabil
JBL
$22.5B
| $982K | ﹤0.01% |
8,195
-838,048
| -99% | -$100M |
|
1605
Pegasystems
PEGA
$9.75B
| $981K | ﹤0.01% |
26,840
+6,866
| +34% | +$251K |
|
1606
Nkarta
NKTX
$147M
| $978K | ﹤0.01% |
216,341
+43,035
| +25% | +$195K |
|
1607
Summit Therapeutics
SMMT
$14B
| $968K | ﹤0.01% |
44,188
-223,964
| -84% | -$4.9M |
|
1608
Acadia Pharmaceuticals
ACAD
$4.28B
| $963K | ﹤0.01% |
62,585
-2,189
| -3% | -$33.7K |
|
1609
Hershey
HSY
$38B
| $958K | ﹤0.01% |
4,993
+1,645
| +49% | +$315K |
|
1610
Amphastar Pharmaceuticals
AMPH
$1.36B
| $957K | ﹤0.01% |
+19,723
| New | +$957K |
|
1611
Beam Therapeutics
BEAM
$2.02B
| $955K | ﹤0.01% |
38,996
-4,112
| -10% | -$101K |
|
1612
Anika Therapeutics
ANIK
$129M
| $948K | ﹤0.01% |
38,378
-1,904
| -5% | -$47K |
|
1613
Build-A-Bear
BBW
$949M
| $940K | ﹤0.01% |
27,353
-225,876
| -89% | -$7.76M |
|
1614
Stanley Black & Decker
SWK
$11.9B
| $934K | ﹤0.01% |
8,485
+3,907
| +85% | +$430K |
|
1615
Taysha Gene Therapies
TSHA
$895M
| $931K | ﹤0.01% |
+463,192
| New | +$931K |
|
|
ANSS
1616
DELISTED
Ansys
ANSS
| $930K | ﹤0.01% |
2,918
+269
| +10% | +$85.7K |
|
1617
Novavax
NVAX
$1.29B
| $923K | ﹤0.01% |
+73,115
| New | +$923K |
|
1618
Aquestive Therapeutics
AQST
$606M
| $922K | ﹤0.01% |
+185,191
| New | +$922K |
|
1619
Toast
TOST
$23.9B
| $915K | ﹤0.01% |
32,320
-12,353
| -28% | -$350K |
|
1620
Rogers Communications
RCI
$19.2B
| $894K | ﹤0.01% |
22,198
+10,917
| +97% | +$439K |
|
1621
OP Bancorp
OPBK
$217M
| $892K | ﹤0.01% |
71,486
| – | – |
|
1622
Black Diamond Therapeutics
BDTX
$174M
| $892K | ﹤0.01% |
204,957
+23,282
| +13% | +$101K |
|
1623
Ultrapar
UGP
$3.98B
| $887K | ﹤0.01% |
228,682
-493
| -0.2% | -$1.91K |
|
1624
Vera Therapeutics
VERA
$1.6B
| $887K | ﹤0.01% |
20,071
-92,568
| -82% | -$4.09M |
|
|
PSTX
1625
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $882K | ﹤0.01% |
308,363
-78,968
| -20% | -$226K |
|